Fulvestrant (Faslodex) demonstrates clinical benefit in heavily pre-treated patients with metastatic breast cancer. - Steger,G.; Bartsch,R.; Wenzel,C.; Plusching,U.; Locker,G.; Mader,R.M.; Zielinski,C.C. (Eur J Cancer, 2003)